close

OraSure Technologies, Inc. develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices. The company's products include OraQuick ADVANCE HIV-1/2, a point-of-care test for antibodies to the human immunodeficiency virus (HIV) type 1 and type 2; OraQuick HIV-1/2 OTC, a point-of-care oral fluid HIV-1/2 test; OraQuick HCV, a point-of-care test for antibodies to the hepatitis C virus; OraSure, an oral fluid collection device for the detection of antibodies to HIV-1; and Intercept, an oral fluid collection device used for oral fluid drugs of abuse testing. It also offers MICRO-PLATE DOA Assays for the detection of drugs in an oral fluid sample; cryosurgical systems—professional for the removal of warts and benign skin lesions; and cryosurgical systems—OTC for the removal of common and plantar warts. In addition, OraSure Technologies provides immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test; and Q.E.D., a point-of-care saliva alcohol test. It develops Homogeneous DOA Assays; cryosurgical systems—OTC for an indication other than common warts or plantar warts; and OraQuick, a point-of-care testing platform. Further, the company provides various diagnostic products, including immunoassays and in vitro diagnostic tests that are used on other specimen types, and medical devices. OraSure Technologies sells its products through direct sales, strategic partnerships, and independent distributors to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities in the United States, Europe, and internationally. It has collaboration agreements with Roche Diagnostics and Schering-Plough Corporation. The company was founded in 1979 and is based in Bethlehem, Pennsylvania.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	9.69
Volume	100070
Volume Avg	268260
52 Week High	11.78
52 Week Low	6.29
PE	N/A
PE (group average)	39
EPS Year	-0.19
EPS change Q/Q	1000%
EPS change Q/Q Yr ago	-66.67%
EPS change Q/Q next Q est	-33.33%
EPS change Y/Y	-142.86%
REV change Q/Q	-1.05%
REV change Q/Q Yr ago	-10.05%
EPS next Q est	-0.03
EPS next Y est	0.08
Divident Annual	0.00
Dividend Yield	0%